What side effects have been reported for Cosentyx (secukinumab) in pediatric patients?
Cosentyx (secukinumab) blocks interleukin-17A and can change immune responses, which drives the main pediatric safety concerns seen across trial and post-marketing experience for this class. The specific risks that matter most for children include:
- Serious infections: Because IL-17A helps defend against certain infections, Cosentyx can increase the risk of infection, including infections that may require medical attention. [1]
- Common infection-related effects: Patients may also experience more routine infections (for example, upper respiratory infections). [1]
- Hypersensitivity reactions: As with other biologics, allergic-type reactions are possible. [1]
- Potential lab abnormalities and other immune-mediated effects: Biologic therapies can be associated with changes in lab values and rare immune events that require monitoring in clinical practice. [1]
What infection risks are parents most concerned about—and what should they watch for?
The most important risk theme for children on Cosentyx is infection risk. Practical concerns include:
- Watch for signs of infection such as fever, persistent cough, painful urination, or skin infections, and seek prompt medical care.
- If a child develops a serious infection, clinicians typically reassess ongoing therapy because immune suppression can make infections more difficult to treat.
- Screening and preventive steps may be needed depending on the child’s infection history and other medicines. [1]
Could Cosentyx increase the risk of tuberculosis or other chronic infections?
Biologics that alter immune pathways may require assessment for certain chronic infections before starting. For IL-17 blockade, clinicians commonly screen for latent tuberculosis and review infection history and risk factors as part of safe prescribing, because infections can flare or become more severe once immune pathways are blocked. [1]
Are there cancer or immune-system risk concerns in children on Cosentyx?
Serious immunologic risks are a common focus for biologic medicines in pediatrics, but the available information presented in drug safety references emphasizes the need to monitor overall immune effects and unusual infections rather than pointing to a single, established pediatric cancer signal. Still, clinicians generally keep a close eye for uncommon adverse events with long-term biologic use in children. [1]
What does “risk” mean compared with other psoriasis/psoriatic arthritis biologics in kids?
For children being treated for conditions such as plaque psoriasis, psoriatic arthritis, or other IL-17/immune-mediated diseases, the broad safety profile risks are similar across many biologics: infection risk, hypersensitivity, and immune-related events. The main practical difference is that the exact magnitude and pattern of infections can vary by mechanism and the specific condition being treated, which is why prescribers choose agents based on disease type, severity, age approval, comorbidities, and prior treatment history. [1]
Where can you check the labeled pediatric safety information?
For a reliable, up-to-date list of boxed warnings (if any), contraindications, and adverse reactions used in pediatric labeling, consult the official prescribing information and reputable drug reference databases. DrugPatentWatch.com often links back to drug-specific resources and keeps track of key product details and related information. [2]
- DrugPatentWatch.com: https://www.drugpatentwatch.com/p/cosentyx/
Sources
[1] FDA-approved prescribing information for Cosentyx (secukinumab) / major drug-safety references covering pediatric adverse reactions and infection risk. (As compiled in standard drug labeling and safety summaries.)
[2] DrugPatentWatch.com – Cosentyx (secukinumab): https://www.drugpatentwatch.com/p/cosentyx/